Patients in the Rehab group received the same baseline assessment as patients in the Prehab group.,Patients Rehab received baseline assessment patients Prehab group.,C0030705|C0034991|C1514756|C0168634|C1261322|C0030705|G0000000|C0441833
"Subjects were instructed to reduce their smoking by replacing as many cigarettes as possible with treatment, either inhaler (nicotine 10 mg or placebo) or gum (nicotine 4 mg or placebo), according to their choice.","Subjects instructed reduce smoking replacing cigarettes treatment, inhaler (nicotine 10 placebo) gum (nicotine 4 placebo), choice.",C0681850|G0000000|G0000000|C0037369|C1299987|C0677453|C0039798|C0021461|C0028040|C0450371|C0032042|C0017562|C0028040|G0000000|C0032042|C0008300
"Finally 20 villages (clusters) were paired, and for each pair one was selected randomly (using a computer generated random number) to receive impregnated bed nets (ITNs), while the other acted as the control village.","Finally 20 villages (clusters) paired, pair selected randomly (using computer generated random number) receive impregnated bed nets (ITNs), acted control village.",G0000000|C0450371|C0562518|C1555715|C1709450|C1709450|C1707391|G0000000|C1524063|C0009622|C3146294|C0034656|C0237753|C1514756|G0000000|C0004916|C1423506|G0000000|C0079613|C0243148|C0562518
Abagovomab 2 mg or placebo was administered as 1-mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.,Abagovomab 2 placebo administered 1-mL suspension 2 weeks 6 weeks (induction phase) 4 weeks (maintenance phase) recurrence 21 months random assignment patient.,C1832044|G0000000|C0032042|C1521801|C0439526|C0038960|G0000000|C0439230|G0000000|C0439230|C0205263|C0205390|G0000000|C0439230|C0024501|C0205390|C0034897|C0450371|C0439231|C0034656|C1516050|C0030705
"When enteral feeding reached 100 cc/kg/day, infants were randomized into two groups: group I, Cases, n=25, where post discharge formula (PDF) was used for fortification, group II, Controls, n=25 with no fortification.","When enteral feeding reached 100 cc/kg/day, infants randomized groups: I, Cases, n=25, post discharge formula (PDF) fortification, II, Controls, n=25 fortification.",G0000000|C1304890|C0204695|C2584321|C1442061|C3538933|C0021270|C0034656|C0441833|C0021966|C0868928|C0369718|C0687676|C0012621|C0489829|C1431343|G0000000|G0000000|C0243148|C0369718|G0000000
"When children made their first quarterly visits from age 15 months onwards, they were randomised in a 1∶1 ratio to receive quarterly albendazole or placebo.","When children quarterly visits age 15 months onwards, randomised 1∶1 ratio receive quarterly albendazole placebo.",G0000000|C0008059|C0332179|C0545082|C0001779|C0450371|C0439231|G0000000|G0000000|G0000000|C0456603|C1514756|C0332179|C0001911|C0032042
Physicians and their patients were randomized to either intervention or control conditions.,Physicians patients randomized intervention control conditions.,C0031831|C0030705|C0034656|C0886296|C0243148|C0012634
"In an open crossover study of CF patients, subjects were randomly allocated to receive either 80 mg tobramycin twice-daily continuous treatment or 300 mg tobramycin twice daily in cycles of 28 days on and 28 days off treatment.","In crossover study CF patients, subjects randomly allocated receive 80 tobramycin twice-daily continuous treatment 300 tobramycin daily cycles 28 days 28 days treatment.",G0000000|C0010366|C0557651|C0009738|C0030705|C0681850|G0000000|G0000000|C1514756|C0450371|C0040341|C0585361|C0549178|C0039798|C1442061|C0040341|C0332173|C1511572|C0450371|C0439228|C0450371|C0439228|C0039798
"Of 266 randomly assigned patients, 178 were assigned to olaparib and 88 to chemotherapy.","Of 266 randomly assigned patients, 178 assigned olaparib 88 chemotherapy.",G0000000|C1442061|G0000000|C1516050|C0030705|C1442061|C1516050|C2316164|C0450371|C0013216
"Patients were instructed to use their placebo patches or transdermal nicotine patches (Nicoderm, Marion Merrell Dow) with the following schedule: 21 mg/d for 6 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks.","Patients instructed placebo patches transdermal nicotine patches (Nicoderm, Marion Merrell Dow) schedule: 21 mg/d 6 weeks, 14 mg/d 2 weeks, 7 mg/d 2 weeks.",C0030705|G0000000|C0032042|C0994894|C0040652|C0028040|C0994894|C0701369|G0000000|G0000000|G0000000|C0086960|C0450371|C0439422|G0000000|C0439230|C0450371|C0439422|G0000000|C0439230|G0000000|C0439422|G0000000|C0439230
"In year 1, 6616 pupils in Group 1 received drug treatment (72.1% of those eligible), with none receiving treatment in Group 2 or 3.","In 1, 6616 pupils Group 1 received drug treatment (72.1% eligible), receiving treatment Group 2 3.",G0000000|G0000000|G0000000|C0034121|C0441833|G0000000|C1514756|C0013227|C0039798|C0450371|C1548635|C1514756|C0039798|C0441833|G0000000|G0000000
"Of the children receiving the spray, 27 (22 of whom could be evaluated) were given penicillin and 103 (86 of whom could be evaluated) amoxicillin clavulanic acid.","Of children receiving spray, 27 (22 evaluated) penicillin 103 (86 evaluated) amoxicillin clavulanic acid.",G0000000|C0008059|C1514756|C1704413|C0450371|C0450371|C0220825|C0030827|C1442061|C0450371|C0220825|C0002645|G0000000|C0001128
The placebo groups received matching treatment that did not contain nicotine.,The placebo received matching treatment nicotine.,G0000000|C0032042|C1514756|C0150103|C0039798|C0028040
"All these areas continued their vitamin A supplementation and other usual care during the study period, and 25 were randomly allocated to offer in addition, 400 mg of albendazole (Zentel, SmithKline Beecham) as 10 ml suspension at the same time as the six-monthly vitamin A.","All continued vitamin A supplementation usual care study period, 25 randomly allocated offer addition, 400 albendazole (Zentel, SmithKline Beecham) 10 suspension time six-monthly vitamin A.",G0000000|C0549178|C0042890|G0000000|C0242297|C3538928|C1947933|C0557651|C0439531|C0450371|G0000000|G0000000|G0000000|C0332287|C1442061|C0001911|C0591462|G0000000|C0331784|C0450371|C0038960|C0040223|C0585339|C0042890|G0000000
"In year 2, 4516 Group 1 pupils (52.1%) and 4159 Group 2 (47.5%) pupils received drug treatment, as well as 91 pupils in Group 3.","In 2, 4516 Group 1 pupils (52.1%) 4159 Group 2 (47.5%) pupils received drug treatment, 91 pupils Group 3.",G0000000|G0000000|G0000000|C0441833|G0000000|C0034121|C0450371|G0000000|C0441833|G0000000|C0450371|C0034121|C1514756|C0013227|C0039798|C0450371|C0034121|C0441833|G0000000
"Women randomly assigned to exercise increased their physical activity by an average 159 minutes per week, compared with 49 minutes per week in the usual-care group (P < .001; Table 2).","Women randomly assigned exercise increased physical activity average 159 minutes week, compared 49 minutes week usual-care (P < .001; Table 2).",C0043210|G0000000|C1516050|C0015259|C0205217|C0031809|C0205177|C1510992|C1442061|C0439232|C0332174|C1707455|C0450371|C0439232|C0332174|C3538928|C0369773|G0000000|C1442061|C0039224|G0000000
"Doses were 10, 40, or 80mg/kg/day, divided q12hr given over 20minutes.","Doses 10, 40, 80mg/kg/day, divided q12hr 20minutes.",C0178602|C0450371|C0450371|C0439418|C0332849|G0000000|G0000000
"To achieve a similar baseline, all patients therefore received colistin (1 million units twice daily) during a washout phase for four or more weeks before being randomly allocated to receive either Tiv80 twice-daily treatment or TIS300 twice-daily treatment in four-weekly on and four-weekly off cycles.","To achieve baseline, patients received colistin (1 units daily) washout phase weeks randomly allocated receive Tiv80 twice-daily treatment TIS300 twice-daily treatment four-weekly four-weekly cycles.",C0040363|G0000000|C0168634|C0030705|C1514756|C0009316|G0000000|C0439148|C0332173|C1710661|C0205390|C0439230|G0000000|G0000000|C1514756|G0000000|C0585361|C0039798|G0000000|C0585361|C0039798|C0205450|C0205450|C1511572
"Children with no recurrences during the last month received phenoxymethylpenicillin (n=22), and those with a recurrence within 1 month received amoxicillin clavulanic acid (n=86), both twice daily for 10 days.","Children recurrences month received phenoxymethylpenicillin (n=22), recurrence 1 month received amoxicillin clavulanic acid (n=86), daily 10 days.",C0008059|C0034897|C0332177|C1514756|C0030840|C0369718|C0034897|G0000000|C0332177|C1514756|C0002645|G0000000|C0001128|C0369718|C0332173|C0450371|C0439228
Consecutive patients were randomly assigned to standard rehabilitation care with or without acupuncture (1:1 allocation ratio).,Consecutive patients randomly assigned standard rehabilitation care acupuncture (1:1 allocation ratio).,C1707491|C0030705|G0000000|C1516050|C1442989|C0034991|C1947933|C0001299|G0000000|C1706778|C0456603
"The acupuncture group also received additional thirty minutes of acupuncture therapy as bedside treatment, six days per week for three weeks (eighteen total sessions).","The acupuncture received additional thirty minutes acupuncture therapy bedside treatment, days week weeks (eighteen total sessions).",G0000000|C0001299|C1514756|C1524062|C3816446|C0439232|C0001299|C0039798|G0000000|C0039798|C0439228|C0332174|C0439230|C3715206|C0439175|C1883016
"This study compared dysphagia treatment effects according to the stimulation site; the cortex, responsible for innervating the suprahyoid muscle, which is related to swallowing, and the motor cortex, responsible for innervating the APB muscle.","This study compared dysphagia treatment effects stimulation site; cortex, responsible innervating suprahyoid muscle, swallowing, motor cortex, responsible innervating APB muscle.",G0000000|C0557651|C1707455|C0011168|C0039798|C1280500|C1292856|C0205145|C0007776|C1273518|G0000000|G0000000|C0026845|C0011167|C1513492|C0007776|C1273518|G0000000|G0000000|C0026845
The intervention also included counseling regarding smoking and alcohol cessation.,The intervention included counseling smoking alcohol cessation.,G0000000|C0886296|C0332257|C0010210|C0037369|C0001962|C1880019
"Electrical stimulation with a maximal tolerable intensity was applied on both suprahyoid muscles for 30 minutes, 5 days per week during 3 weeks.","Electrical stimulation maximal tolerable intensity applied suprahyoid muscles 30 minutes, 5 days week 3 weeks.",C0013790|C1292856|C0205289|C4053931|C0522510|C4048755|G0000000|C0026845|C0450371|C0439232|G0000000|C0439228|C0332174|G0000000|C0439230
"The intervention was rolled out in ‘steps’, with Group 1 receiving the intervention in year 1, Group 2 in year 2 and Group 3 in the year after the study.","The intervention rolled ‘steps’, Group 1 receiving intervention 1, Group 2 2 Group 3 study.",G0000000|C0886296|C3841382|G0000000|C0441833|G0000000|C1514756|C0886296|G0000000|C0441833|G0000000|G0000000|C0441833|G0000000|C0557651
"Using a two-group design (usual care (UC) versus nicotine patches at discharge plus proactive quitline counseling), 126 subjects were recruited, randomized, and evaluated at two months.","Using two-group design (usual care (UC) versus nicotine patches discharge proactive quitline counseling), 126 subjects recruited, randomized, evaluated months.",C1524063|C0205448|C1707689|C3538928|C1947933|G0000000|G0000000|C0028040|C0994894|C0012621|G0000000|G0000000|C0010210|C1442061|C0681850|G0000000|C0034656|C0220825|C0439231
"We randomized 14 federally funded community health center dental clinics that serve diverse racial/ethnic groups in 3 states (Mississippi, New York, and Oregon) to the intervention (brief advice and assistance, including nicotine replacement therapy) or usual care group.","We randomized 14 federally funded community health center dental clinics serve diverse racial/ethnic 3 (Mississippi, New York, Oregon) intervention (brief advice assistance, including nicotine replacement therapy) usual care group.",G0000000|C0034656|C0450371|G0000000|C0016820|C0009462|C0018684|C0205099|C0011365|C0442592|G0000000|C1880371|C0034510|G0000000|C0026221|C0205314|G0000000|C0029195|C0886296|C1282927|C0150600|C0018896|C0332257|C0028040|C0035139|C0039798|C3538928|C1947933|C0441833
"From age 15 to 21 months, children received syrups (5 ml) equivalent to 200 mg albendazole or matching placebo, labelled according to the randomisation code by the manufacturer.","From age 15 21 months, children received syrups (5 ml) equivalent 200 albendazole matching placebo, labelled randomisation code manufacturer.",G0000000|C0001779|C0450371|C0450371|C0439231|C0008059|C1514756|C0458173|G0000000|C0439526|C0205163|C1442061|C0001911|C0150103|C0032042|C0181496|C0034656|C0009219|C0947322
Participants were randomly assigned to exercise (150 minutes per week of aerobic exercise and supervised strength training twice per week) or usual care.,Participants randomly assigned exercise (150 minutes week aerobic exercise supervised strength training week) usual care.,C0679646|G0000000|C1516050|C0015259|C1442061|C0439232|C0332174|C1510824|C0015259|G0000000|C0237897|C0040607|C0332174|C3538928|C1947933
At day 60 the same spray was started for another 10 days.,At day 60 spray started 10 days.,G0000000|C0332173|C0450371|C1704413|C1272689|C0450371|C0439228
"Route of administration is either oral, sublingual or via nasogastric tube, dependent on swallow safety, which is assessed as part of routine care after admission.","Route administration oral, sublingual nasogastric tube, dependent swallow safety, assessed routine care admission.",C0013153|C0001554|C0442027|C0001565|C0694637|C0175730|C0851827|C0326374|C0036043|C1516048|C0205547|C1947933|C0184666
Group B received rTMS over the brain cortex where MEP was obtained from the abductor pollicis brevis muscle.,Group B received rTMS brain cortex MEP abductor pollicis brevis muscle.,C0441833|G0000000|C1514756|G0000000|C0006104|C0007776|C1707163|G0000000|G0000000|G0000000|C0026845
Twenty five were assigned to standard services and 25 to standard services plus treatment with albendazole.,Twenty assigned standard services 25 standard services treatment albendazole.,C0724000|C1516050|C1442989|C0557854|C0450371|C1442989|C0557854|C0039798|C0001911
"At randomization, patients received 2 weeks of 21 mg/d patches and received the remaining 4 weeks of 21 mg/d at the 1-week visit.","At randomization, patients received 2 weeks 21 mg/d patches received remaining 4 weeks 21 mg/d 1-week visit.",G0000000|C0034656|C0030705|C1514756|G0000000|C0439230|C0450371|C0439422|C0994894|C1514756|C1527428|G0000000|C0439230|C0450371|C0439422|C0332174|C0545082
"Pentobarbital was administered in accordance with the protocol established by Eisenberg and coworkers [10], using a loading dose of 10 mg/kg over 30 minutes followed by a continuous perfusion of 5 mg/kg per hour for 3 hours.","Pentobarbital administered protocol established Eisenberg coworkers [10], loading dose 10 mg/kg 30 minutes continuous perfusion 5 mg/kg hour 3 hours.",C0030883|C1521801|C0442711|C0443211|G0000000|C0681088|C0450371|C1708715|C0178602|C0450371|C0439272|C0450371|C0439232|C0549178|C0031001|G0000000|C0439272|C0439227|G0000000|C0439227
The intervention was introduced over 2 years: Group 1 schools received the intervention in both years; Group 2 schools received the intervention in year 2 only and were in the control arm in year 1; and Group 3 schools did not receive the intervention in either year (Figure 2).,The intervention introduced 2 years: Group 1 schools received intervention years; Group 2 schools received intervention 2 control arm 1; Group 3 schools receive intervention (Figure 2).,G0000000|C0886296|C1292748|G0000000|C0439234|C0441833|G0000000|C0036375|C1514756|C0886296|C0439234|C0441833|G0000000|C0036375|C1514756|C0886296|G0000000|C0243148|C0446516|G0000000|C0441833|G0000000|C0036375|C1514756|C0886296|G0000000|G0000000
"All patients were scheduled to receive darbepoetin alfa (Aranesp; Amgen, Thousand Oaks, CA) 500 μg subcutaneously every 3 weeks until Hb reached greater than 11.0 g/dL and thereafter to receive maintenance darbepoetin 300 μg every 3 weeks.","All patients scheduled receive darbepoetin alfa (Aranesp; Amgen, Thousand Oaks, CA) 500 μg subcutaneously 3 weeks Hb reached 11.0 g/dL receive maintenance darbepoetin 300 μg 3 weeks.",G0000000|C0030705|C0086960|C1514756|G0000000|C0439095|C1134440|C0331771|C1883310|C0330302|C3887642|C1442061|G0000000|G0000000|G0000000|C0439230|C0019046|C2584321|C0450371|C0439267|C1514756|C0024501|G0000000|C1442061|G0000000|G0000000|C0439230
Eligible patients were randomly assigned 1:1 to receive a 4-week prehabilitation program (Prehab group) or a 4-week postoperative rehabilitation program (Rehab group).,Eligible patients randomly assigned 1:1 receive 4-week prehabilitation program (Prehab group) 4-week postoperative rehabilitation program (Rehab group).,C1548635|C0030705|G0000000|C1516050|G0000000|C1514756|C0332174|G0000000|C1709697|G0000000|C0441833|C0332174|C0032790|C0034991|C1709697|C0034991|C0441833
"After matching sample townships into pairs, we randomly assigned one township in each pair to either a control or intervention group.","After matching sample townships pairs, randomly assigned township pair control intervention group.",G0000000|C0150103|C0370003|C1552925|C1709450|G0000000|C1516050|C1552925|C1709450|C0243148|C0886296|C0441833
Infants of 23–29 weeks gestation were randomized to a single intravenous (IV) dose of inositol at 60 or 120 mg/kg or placebo.,Infants 23–29 weeks gestation randomized single intravenous (IV) dose inositol 60 120 mg/kg placebo.,C0021270|G0000000|C0439230|C0032961|C0034656|C0037179|C0348016|C0022326|C0178602|C0021547|C0450371|C1442061|C0439272|C0032042
"Initial ‘Treatment Phase’ involved three groups receiving either sertaconazole 2% cream applied topically twice daily for four weeks, terbinafine 1% cream once daily for two weeks, luliconazole 1% cream once daily for two weeks.","Initial ‘Treatment Phase’ involved receiving sertaconazole 2% cream applied topically daily weeks, terbinafine 1% cream daily weeks, luliconazole 1% cream daily weeks.",C0205265|G0000000|G0000000|C1314939|C1514756|C0074391|G0000000|C0700385|C4048755|G0000000|C0332173|C0439230|C0076110|G0000000|C0700385|C0332173|C0439230|C1956280|G0000000|C0700385|C0332173|C0439230
"Women with a SCL ≥ 100 ng/ml received 21 mg patches for 2 weeks, 14 mg patches for 4 weeks, and 7 mg patches for 4 weeks.","Women SCL ≥ 100 ng/ml received 21 patches 2 weeks, 14 patches 4 weeks, 7 patches 4 weeks.",C0043210|G0000000|G0000000|C1442061|C0439275|C1514756|C0450371|C0994894|G0000000|C0439230|C0450371|C0994894|G0000000|C0439230|G0000000|C0994894|G0000000|C0439230
"In each of the seven counties included in our study, we randomly assigned half of the townships within each county to the control group and the other half to the intervention group.","In counties included study, randomly assigned half townships county control half intervention group.",G0000000|C0079170|C0332257|C0557651|G0000000|C1516050|C2825407|C1552925|C0079170|C0243148|C2825407|C0886296|C0441833
"[15] Briefly, healthy pregnant women from the study area, and planning to deliver in Entebbe Hospital, pregnant women were assigned in a 1∶1∶1∶1 ratio to receive simultaneously single-dose albendazole (400 mg) and praziquantel (40 mg/kg), or albendazole and a praziquantel-matching placebo, or an albendazole-matching placebo and praziquantel, or an albendazole-matching placebo and a praziquantel-matching placebo (albendazole and matching placebo: GlaxoSmithKline, Brentford, UK; praziquantel tablets, (Medochemie Ltd, Limassol, Cyprus) were used to prepare identical praziquantel 300 mg and placebo capsules (Almedica Europe Ltd, Deeside, UK)).","[15] Briefly, healthy pregnant women study area, planning deliver Entebbe Hospital, pregnant women assigned 1∶1∶1∶1 ratio receive simultaneously single-dose albendazole (400 mg) praziquantel (40 mg/kg), albendazole praziquantel-matching placebo, albendazole-matching placebo praziquantel, albendazole-matching placebo praziquantel-matching placebo (albendazole matching placebo: GlaxoSmithKline, Brentford, UK; praziquantel tablets, (Medochemie Ltd, Limassol, Cyprus) prepare identical praziquantel 300 placebo capsules (Almedica Europe Ltd, Deeside, UK)).",C0450371|G0000000|C3898900|C0549206|C0043210|C0557651|C0017446|C0032074|C0308779|G0000000|C0019994|C0549206|C0043210|C1516050|G0000000|C0456603|C1514756|C0521115|C0037179|C0001911|C1442061|C0026410|C0032911|C0450371|C0439272|C0001911|C0032911|C0032042|C0001911|C0032042|C0032911|C0001911|C0032042|C0032911|C0032042|C0001911|C0150103|C0032042|C1552903|G0000000|C0041700|C0032911|C0039225|G0000000|C1136140|G0000000|C0010622|C1521827|C0205280|C0032911|C1442061|C0032042|C0006935|G0000000|C0015176|C1136140|G0000000|C0041700
Children aged one to four years were randomly assigned to receive either albendazole or placebo every four months for 12 months with a follow-up at 14 months.,Children aged randomly assigned receive albendazole placebo months 12 months follow-up 14 months.,C0008059|C0001779|G0000000|C1516050|C1514756|C0001911|C0032042|C0439231|C0450371|C0439231|C0589120|C0450371|C0439231
Thiopental was administered in the form of a 2 mg/kg bolus administered over 20 seconds.,Thiopental administered form 2 mg/kg bolus administered 20 seconds.,C0039925|C1521801|C0348078|G0000000|C0439272|C1511237|C1521801|C0450371|C0457385
"Antibiotic treatment—Those children with no recurrences during the past month but who had acute otitis media were given phenoxymethylpenicillin (Kåvepenin, AstraZeneca, Sweden) 25 mg/kg bodyweight.","Antibiotic treatment—Those children recurrences month acute otitis media phenoxymethylpenicillin (Kåvepenin, AstraZeneca, Sweden) 25 mg/kg bodyweight.",C0003232|G0000000|C0008059|C0034897|C0332177|C0205178|C0029877|C0009458|C0030840|G0000000|G0000000|C0038995|C0450371|C0439272|C0005910
"Patients were randomly assigned 2:1 to olaparib tablets 300 mg twice a day or to physician’s choice of single-agent chemotherapy: PLD 50 mg/m2 on day 1 every 4 weeks; paclitaxel 80 mg/m2 on days 1, 8, 15, and 22 every 4 weeks; gemcitabine 1,000 mg/m2 on days 1, 8, and 15 every 4 weeks; or topotecan 4 mg/m2 on days 1, 8, and 15 every 4 weeks.","Patients randomly assigned 2:1 olaparib tablets 300 day physician’s choice single-agent chemotherapy: PLD 50 mg/m2 day 1 4 weeks; paclitaxel 80 mg/m2 days 1, 8, 15, 22 4 weeks; gemcitabine 1,000 mg/m2 days 1, 8, 15 4 weeks; topotecan 4 mg/m2 days 1, 8, 15 4 weeks.",C0030705|G0000000|C1516050|G0000000|C2316164|C0039225|C1442061|C0332173|G0000000|C0008300|C0037179|C0013216|C0044369|C0450371|C0026410|C0332173|G0000000|G0000000|C0439230|C0144576|C0450371|C0026410|C0439228|G0000000|G0000000|C0450371|C0450371|G0000000|C0439230|C0045093|C1442061|C0026410|C0439228|G0000000|G0000000|C0450371|G0000000|C0439230|C0146224|G0000000|C0026410|C0439228|G0000000|G0000000|C0450371|G0000000|C0439230
"Patients and investigators were blinded to assignment of oral iron or oral placebo, but, for practical reasons, assignment to IV iron versus an oral product was not blinded.","Patients investigators blinded assignment oral iron oral placebo, but, practical reasons, assignment IV iron versus oral product blinded.",C0030705|C0035173|C0150108|C1516050|C0442027|C0302583|C0442027|C0032042|G0000000|G0000000|C0392360|C1516050|C0022326|C0302583|G0000000|C0442027|C1514468|C0150108
"The patients were divided into two groups according to the stimulation site: group A underwent stimulation of the cortex representing the suprahyoid muscle of the affected side, while group B underwent stimulation of the cortex representing the abductor pollicis brevis (APB) of the affected side.","The patients divided stimulation site: A underwent stimulation cortex representing suprahyoid muscle side, B underwent stimulation cortex representing abductor pollicis brevis (APB) side.",G0000000|C0030705|C0332849|C1292856|C0205145|G0000000|G0000000|C1292856|C0007776|C1882932|G0000000|C0026845|C0441987|G0000000|G0000000|C1292856|C0007776|C1882932|G0000000|G0000000|G0000000|G0000000|C0441987
"Both groups received conventional stroke rehabilitation care according to Chinese stroke rehabilitation treatment guidelines [15], which began as soon as the diagnosis of stroke was established and life-threatening conditions were under control.","Both received conventional stroke rehabilitation care Chinese stroke rehabilitation treatment guidelines [15], diagnosis stroke established life-threatening conditions control.",G0000000|C1514756|C0439858|C0038454|C0034991|C1947933|C0008120|C0038454|C0034991|C0039798|C0162791|C0450371|C0011900|C0038454|C0443211|C1517874|C0012634|C0243148
"[17] As previously described, the study, based at Entebbe General Hospital, Uganda, was a trial with three randomised, double-blind, placebo-controlled interventions at two times, in a 2×2(×2) factorial design: women were randomised to albendazole versus placebo and praziquantel versus placebo during pregnancy; their children were randomised to quarterly albendazole versus placebo from age 15 months to 5 years [ISRCTN32849447].","[17] As described, study, based Entebbe General Hospital, Uganda, trial randomised, double-blind, placebo-controlled interventions times, 2×2(×2) factorial design: women randomised albendazole versus placebo praziquantel versus placebo pregnancy; children randomised quarterly albendazole versus placebo age 15 months 5 [ISRCTN32849447].",C0450371|G0000000|C1552738|C0557651|C1527178|G0000000|C0205246|C0019994|C0041573|C0008976|G0000000|C0013072|C1706408|C0886296|C0040223|G0000000|C2826344|C1707689|C0043210|G0000000|C0001911|G0000000|C0032042|C0032911|G0000000|C0032042|C0032961|C0008059|G0000000|C0332179|C0001911|G0000000|C0032042|C0001779|C0450371|C0439231|G0000000|G0000000
"Subjects are randomly assigned into: usual care, nicotine patches, telephone counseling, or both patches and counseling.","Subjects randomly assigned into: usual care, nicotine patches, telephone counseling, patches counseling.",C0681850|G0000000|C1516050|G0000000|C3538928|C1947933|C0028040|C0994894|C0039457|C0010210|C0994894|C0010210
Albendazole was offered as one 400 mg chewable tablet (Zentel: GlaxoSmithKline) to all healthy children aged 1-7 years who attended any child health day.,Albendazole offered 400 chewable tablet (Zentel: GlaxoSmithKline) healthy children aged 1-7 attended child health day.,C0001911|C1444648|C1442061|G0000000|C0039225|C0591462|C1552903|C3898900|C0008059|C0001779|G0000000|C1456498|C0008059|C0018684|C0332173
"Of the 178 patients randomly assigned to olaparib and 88 to chemotherapy (PLD, n = 47; paclitaxel, n = 20; gemcitabine, n = 13; topotecan, n = 8; intent-to-treat population), all 178 patients in the olaparib group and 76 in the chemotherapy group received treatment (safety analysis set).","Of 178 patients randomly assigned olaparib 88 chemotherapy (PLD, = 47; paclitaxel, = 20; gemcitabine, = 13; topotecan, = 8; intent-to-treat population), 178 patients olaparib 76 chemotherapy received treatment (safety analysis set).",G0000000|C1442061|C0030705|G0000000|C1516050|C2316164|C0450371|C0013216|C0044369|G0000000|C0450371|C0144576|G0000000|C0450371|C0045093|G0000000|C0450371|C0146224|G0000000|G0000000|C0162425|C0032659|C1442061|C0030705|C2316164|C0450371|C0013216|C1514756|C0039798|C0036043|C0002778|C0036849
"This multi-center, double-blind placebo-controlled study evaluated the efficacy and safety of nicotine 4 mg gum or nicotine 10 mg inhaler in helping smokers (N = 314) to reduce or quit smoking.","This multi-center, double-blind placebo-controlled study evaluated efficacy safety nicotine 4 gum nicotine 10 inhaler helping smokers (N = 314) reduce quit smoking.",G0000000|C0439743|C0013072|C1706408|C0557651|C0220825|C1280519|C0036043|C0028040|G0000000|C0017562|C0028040|C0450371|C0021461|G0000000|C0337664|C0369718|G0000000|C1442061|G0000000|C0748223|C0037369
All patients were treated within a standardized enhanced recovery pathway.,All patients treated standardized enhanced recovery pathway.,G0000000|C0030705|C1522326|G0000000|C2349975|C0237820|C1704259
Women with a baseline SCL ≥ 20 and ≤100 ng/ml received 14 mg patches for 6 weeks and 7 mg patches for 4 weeks.,Women baseline SCL ≥ 20 ≤100 ng/ml received 14 patches 6 weeks 7 patches 4 weeks.,C0043210|C0168634|G0000000|G0000000|C0450371|G0000000|C0439275|C1514756|C0450371|C0994894|G0000000|C0439230|G0000000|C0994894|G0000000|C0439230
"Between the 26th and 29th of April 1998, all households in the intervention villages received a number of ITNs, according to the number of family members and were instructed explicitly about the correct use of the nets (Figure 2).","Between 26th 29th April 1998, households intervention villages received ITNs, family instructed explicitly correct nets (Figure 2).",G0000000|G0000000|G0000000|C3715024|G0000000|C0020052|C0886296|C0562518|C1514756|G0000000|C0015576|G0000000|G0000000|C2349182|C1423506|G0000000|G0000000
Schools in the control arm received neither component of the intervention.,Schools control arm received component intervention.,C0036375|C0243148|C0446516|C1514756|C0449432|C0886296
"Patients were randomly assigned on a 1:1:1 basis to receive either sodium ferric gluconate complex in sucrose (Ferrlecit; Watson, Morristown, NJ) 187.5 mg IV over 90 minutes once every 3 weeks for five doses (total dose 937.5 mg), oral ferrous sulfate 325 mg once daily, or an oral placebo.","Patients randomly assigned 1:1:1 basis receive sodium ferric gluconate complex sucrose (Ferrlecit; Watson, Morristown, NJ) 187.5 IV 90 minutes 3 weeks doses (total dose 937.5 mg), oral ferrous sulfate 325 daily, oral placebo.",C0030705|G0000000|C1516050|G0000000|C1527178|C1514756|C0037473|C2346593|C0017714|C0439855|C0038636|C0117571|C3476816|G0000000|C0027971|C1442061|C0022326|C0450371|C0439232|G0000000|C0439230|C0178602|C0439175|C0178602|C1442061|C0026410|C0442027|C2346592|C0038720|C1442061|C0332173|C0442027|C0032042
This was followed by a maintenance dosage of 1 mg/kg per hour.,This maintenance dosage 1 mg/kg hour.,G0000000|C0024501|C0178602|G0000000|C0439272|C0439227
"We conducted a prospective, randomized cohort study comparing two treatments: pentobarbital and thiopental.","We conducted prospective, randomized cohort study comparing treatments: pentobarbital thiopental.",G0000000|C0004927|C0023981|C0034656|C0599755|C0557651|C1707455|C0087111|C0030883|C0039925
Women were randomly assigned (1:2) to the intervention group or control group.,Women randomly assigned (1:2) intervention control group.,C0043210|G0000000|C1516050|G0000000|C0886296|C0243148|C0441833
Intervention Treatment of children aged between 1 and 7 years with 400 mg albendazole added to standard services offered during child health days over a three year period.,Intervention Treatment children aged 1 7 400 albendazole standard services offered child health days period.,C0886296|C0039798|C0008059|C0001779|G0000000|G0000000|C1442061|C0001911|C1442989|C0557854|C1444648|C0008059|C0018684|C0439228|C0439531
"Over 12 months, women randomly assigned to exercise (n = 61) attended 70% (± standard deviation [SD], 28%) of resistance training sessions and increased their exercise by 159 (± SD, 136) minutes per week.","Over 12 months, women randomly assigned exercise (n = 61) attended 70% (± standard deviation [SD], 28%) resistance training sessions increased exercise 159 (± SD, 136) minutes week.",C0205136|C0450371|C0439231|C0043210|G0000000|C1516050|C0015259|C0369718|G0000000|C0450371|C1456498|C0450371|G0000000|C1442989|C0012727|C2699239|C0450371|C0237834|C0040607|C1883016|C0205217|C0015259|C1442061|G0000000|C2699239|C1442061|C0439232|C0332174
"In this randomized, open-label trial, patients were randomly assigned 2:1 to olaparib 300 mg twice a day or physician’s choice single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan).","In randomized, open-label trial, patients randomly assigned 2:1 olaparib 300 day physician’s choice single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, topotecan).",G0000000|C0034656|C1709323|C0008976|C0030705|G0000000|C1516050|G0000000|C2316164|C1442061|C0332173|G0000000|C0008300|C0037179|G0000000|C0013216|G0000000|C0023828|C0013089|C0144576|C0045093|C0146224
"A 40-mg/kg dose of myo-inositol was given every 12 hours (initially intravenously, then enterally when feeding; n = 317) or placebo (n = 321) for up to 10 weeks.","A 40-mg/kg dose myo-inositol 12 hours (initially intravenously, enterally feeding; n = 317) placebo (n = 321) 10 weeks.",G0000000|C0450371|C0178602|C0021547|C0450371|C0439227|C0205265|G0000000|G0000000|C0204695|G0000000|C0032042|G0000000|C0450371|C0439230
These were followed by a streptococcal or placebo solution sprayed into the nose for a further 10 days.,These streptococcal placebo solution sprayed nose 10 days.,G0000000|C0038402|C0032042|C0037633|C0233601|C0028429|C0450371|C0439228
"Patients were randomly assigned to sham, and low and high frequency stimulation groups.","Patients randomly assigned sham, low frequency stimulation groups.",C0030705|G0000000|C1516050|C0068899|C0205251|C0376249|C1292856|C0441833
"Using the multiphase optimization strategy (MOST), 1,034 smokers who entered a Web site for smokers (smokefree.gov) were randomly assigned to the “on” and “off” conditions of five smoking cessation interventions: the National Cancer Institute’s (NCI) Web site (www.smokefree.gov vs a “lite” Web site), telephone quitline counseling (vs none), a smoking cessation brochure (vs a lite brochure), motivational e-mail messages (vs none), and mini-lozenge nicotine replacement therapy (NRT vs none).","Using multiphase optimization strategy (MOST), 1,034 smokers entered Web site smokers (smokefree.gov) randomly assigned “on” “off” conditions smoking cessation interventions: National Cancer Institute’s (NCI) Web site (www.smokefree.gov “lite” Web site), telephone quitline counseling (vs none), smoking cessation brochure (vs lite brochure), motivational e-mail messages (vs none), mini-lozenge nicotine replacement therapy (NRT none).",C1524063|G0000000|C2698650|C0679199|C0205393|C1442061|C0337664|C1521975|C0282111|C0205145|C0337664|C1419208|G0000000|C1516050|G0000000|G0000000|C0012634|C0037369|C1880019|C0886296|C3245503|C0006826|G0000000|C1513882|C0282111|C0205145|C0282111|G0000000|C0282111|C0205145|C0039457|G0000000|C0010210|G0000000|G0000000|C0037369|C1880019|C0030258|G0000000|G0000000|C0030258|C0026605|C0013849|C0470166|G0000000|G0000000|C0445542|C0028040|C0035139|C0039798|C1278444|G0000000
"There were 434 randomized subjects, 215 allocated to ALB and 219 to saline treatment.","There 434 randomized subjects, 215 allocated ALB 219 saline treatment.",G0000000|C1442061|C0034656|C0681850|C1442061|G0000000|G0000000|C1442061|C0036082|C0039798
All patients received counseling after being randomly assigned to a 2 mg nicotine gum or a placebo gum group.,All patients received counseling randomly assigned 2 nicotine gum placebo gum group.,G0000000|C0030705|C1514756|C0010210|G0000000|C1516050|G0000000|C0028040|C0017562|C0032042|C0017562|C0441833
1228 subjects were randomised into this study; 625 to albendazole and 603 to placebo.,1228 subjects randomised study; 625 albendazole 603 placebo.,G0000000|C0681850|G0000000|C0557651|C1442061|C0001911|C1442061|C0032042
"We randomly assigned women aged 39–41 years, using individual randomisation, stratified by general practice, in a 1:2 ratio, to yearly mammographic screening from the year of inclusion in the trial up to and including the calendar year that they reached age 48 years (intervention group), or to standard care of no screening until the invitation to their first National Health Service Breast Screening Programme (NHSBSP) screen at approximately age 50 years (control group).","We randomly assigned women aged 39–41 years, individual randomisation, stratified practice, 1:2 ratio, yearly mammographic screening inclusion trial including calendar reached age 48 (intervention group), standard care screening invitation National Health Service Breast Screening Programme (NHSBSP) screen age 50 (control group).",G0000000|G0000000|C1516050|C0043210|C0001779|G0000000|C0439234|C0027361|C0034656|C0205363|C0237607|G0000000|C0456603|C0332181|C0024671|C0220908|C0007637|C0008976|C0332257|C1516147|C2584321|C0001779|C0450371|C0886296|C0441833|C1442989|C1947933|C0220908|C2826348|C3245503|C0018684|C0557854|C0006141|C0220908|C1709697|G0000000|C0220908|C0001779|C0450371|C0243148|C0441833
Subjects randomized into the patch condition receive an eight-week supply of nicotine patches.,Subjects randomized patch condition receive eight-week supply nicotine patches.,C0681850|C0034656|C0332461|C0012634|C1514756|C0205454|C0243163|C0028040|C0994894
"Those children with a recurrence within the past month were given amoxicillin clavulanic acid (Spektramox, AstraZeneca) 20 mg/kg bodyweight.","Those children recurrence month amoxicillin clavulanic acid (Spektramox, AstraZeneca) 20 mg/kg bodyweight.",G0000000|C0008059|C0034897|C0332177|C0002645|G0000000|C0001128|C0729071|G0000000|C0450371|C0439272|C0005910
Two hundred fifty patients were randomized into two groups: acupuncture (AG) or no acupuncture (NAG).,Two fifty patients randomized groups: acupuncture (AG) acupuncture (NAG).,C0205448|C3816723|C0030705|C0034656|C0441833|C0001299|C0002037|C0001299|C1709111
To compare the outcome of an early application of neuromuscular electrical stimulation (NMES) combined with traditional dysphagia therapy (TDT) versus traditional dysphagia therapy only in acute/subacute ischemic stroke patients with moderate to severe dysphagia by videofluoroscopic swallowing study (VFSS).,To compare outcome application neuromuscular electrical stimulation (NMES) combined traditional dysphagia therapy (TDT) versus traditional dysphagia therapy acute/subacute ischemic stroke patients moderate severe dysphagia videofluoroscopic swallowing study (VFSS).,C0040363|C1707455|C1274040|C0185125|C1979768|C0013790|C1292856|C2985393|C0205195|C0443324|C0011168|C0039798|C3887634|G0000000|C0443324|C0011168|C0039798|C0205178|C0475224|C0038454|C0030705|C0205081|C0205082|C0011168|C1660599|C0011167|C0557651|G0000000
"Intervention: Lisinopril 5-10 mg (intervention group), matched placebo (control group), daily for 7 days.","Intervention: Lisinopril 5-10 (intervention group), matched placebo (control group), daily 7 days.",C0886296|C0065374|C0450371|C0886296|C0441833|C0150103|C0032042|C0243148|C0441833|C0332173|G0000000|C0439228
"Patients in the control group only received conventional stroke rehabilitation care, which was the same as the acupuncture group.","Patients control received conventional stroke rehabilitation care, acupuncture group.",C0030705|C0243148|C1514756|C0439858|C0038454|C0034991|C1947933|C0001299|C0441833
"In brief, women aged 39–41 years were randomly assigned to yearly screening up to and including the calendar year that they reached age 48 years (intervention group), or to usual care, which was no screening until the first National Health Service Breast Screening Programme (NHSBSP) screen at approximately 50 years of age (control group).","In brief, women aged 39–41 randomly assigned yearly screening including calendar reached age 48 (intervention group), usual care, screening National Health Service Breast Screening Programme (NHSBSP) screen 50 age (control group).",G0000000|C1282927|C0043210|C0001779|G0000000|G0000000|C1516050|C0332181|C0220908|C0332257|C1516147|C2584321|C0001779|C0450371|C0886296|C0441833|C3538928|C1947933|C0220908|C3245503|C0018684|C0557854|C0006141|C0220908|C1709697|G0000000|C0220908|C0450371|C0001779|C0243148|C0441833
"Group A, repetitive transcranial magnetic stimulation (rTMS) of the cortex representing the suprahyoid muscle; group B, rTMS of the cortex representing the abductor pollicis brevis; MMSE, Mini-Mental Status Examination; K-MBI, Korean version of Modified Barthel Index.","Group A, repetitive transcranial magnetic stimulation (rTMS) cortex representing suprahyoid muscle; B, rTMS cortex representing abductor pollicis brevis; MMSE, Mini-Mental Status Examination; K-MBI, Korean version Modified Barthel Index.",C0441833|G0000000|G0000000|C0442348|C0024488|C1292856|G0000000|C0007776|C1882932|G0000000|C0026845|G0000000|G0000000|C0007776|C1882932|G0000000|G0000000|G0000000|C0451306|C0445542|C0449438|G0000000|C0597277|C1556095|C0333052|C0392747|G0000000|C0918012
"Group I (Cases, n=25) where PDF was used for fortification of mothers’ breast milk, and group II (Controls, n=25) where no fortification was added.","Group I (Cases, n=25) PDF fortification mothers’ breast milk, II (Controls, n=25) fortification added.",C0441833|C0021966|C0868928|C0369718|C1431343|G0000000|G0000000|C0006141|C0026131|G0000000|C0243148|C0369718|G0000000|C1524062
"Patients were randomly assigned to high-frequency, low-frequency, and sham stimulation groups.","Patients randomly assigned high-frequency, low-frequency, sham stimulation groups.",C0030705|G0000000|C1516050|C0205212|C0205213|C0068899|C1292856|C0441833
Children in the placebo group were treated with albendazole at the end of the study.,Children placebo treated albendazole study.,C0008059|C0032042|C1522326|C0001911|C0557651
The present study was designed to compare the effect of continuous twice daily inhalation of 80 mg tobramycin intravenous preparation (Tiv80) with that of intermittent administration of 300 mg preservative-free tobramycin solution for inhalation (TIS300) in CF patients chronically infected with P aeruginosa in an outpatient clinic setting.,The study designed compare continuous daily inhalation 80 tobramycin intravenous preparation (Tiv80) intermittent administration 300 preservative-free tobramycin solution inhalation (TIS300) CF patients chronically infected P aeruginosa outpatient clinic setting.,G0000000|C0557651|C1707689|C1707455|C0549178|C0332173|C0004048|C0450371|C0040341|C0348016|C1521827|G0000000|C0205267|C0001554|C1442061|C0033086|C0040341|C0037633|C0004048|G0000000|C0009738|C0030705|G0000000|C0439663|C0369773|G0000000|C0029921|C0002424|C0542559
Thirty-one patients received NMES combined with TDT (NMES/TDT group) and 26 patients received TDT only (TDT group).,Thirty-one patients received NMES combined TDT (NMES/TDT group) 26 patients received TDT (TDT group).,C3816446|C0030705|C1514756|C2985393|C0205195|C3887634|C2985393|C0441833|C0450371|C0030705|C1514756|C3887634|C3887634|C0441833
Participants receive lisinopril (5-10 mg) or matched placebo daily for 7 days.,Participants receive lisinopril (5-10 mg) matched placebo daily 7 days.,C0679646|C1514756|C0065374|C0450371|C0026410|C0150103|C0032042|C0332173|G0000000|C0439228
53 883 women (33·5%) were randomly assigned to the intervention group and 106 953 (66·5%) to the control group.,53 883 women (33·5%) randomly assigned intervention 106 953 (66·5%) control group.,G0000000|C0043210|G0000000|G0000000|C1516050|C0886296|G0000000|G0000000|C0243148|C0441833
"Thus, half of the participants were randomly assigned to one level of each factor (e.g., active mini-lozenge), and the other half were assigned to the other level of each factor (e.g., no mini-lozenge, see Table 1).","Thus, half participants randomly assigned level factor (e.g., active mini-lozenge), half assigned level factor (e.g., mini-lozenge, Table 1).",G0000000|C2825407|C0679646|G0000000|C1516050|C0441889|C1521761|G0000000|C0205177|C0445542|C2825407|C1516050|C0441889|C1521761|G0000000|C0445542|C0039224|G0000000
"There were two groups: a cognitive behavioral therapy (CBT) control group and a CBT plus NRT (choice: patch, gum or lozenges) group.","There groups: cognitive behavioral therapy (CBT) control CBT NRT (choice: patch, gum lozenges) group.",G0000000|C0441833|C1516691|C0004927|C0039798|C0009244|C0243148|C0009244|C1278444|C0008300|C0332461|C0017562|C0991564|C0441833
"We sought to compare the effectiveness of a dental practitioner advice and brief counseling intervention to quit tobacco use versus usual care for patients in community health centers on tobacco cessation, reduction in tobacco use, number of quit attempts, and change in readiness to quit.","We sought compare effectiveness dental practitioner advice counseling intervention quit tobacco versus usual care patients community health centers tobacco cessation, reduction tobacco use, quit attempts, change readiness quit.",G0000000|G0000000|C1707455|C1280519|C0011365|C1709627|C0150600|C0010210|C0886296|C0748223|C0040329|G0000000|C3538928|C1947933|C0030705|C0009462|C0018684|C0205099|C0040329|C1880019|C0301630|C0040329|C0042153|C0748223|C1516084|C0392747|C1318963|C0748223
"Depending on assigned condition, smokers may receive nicotine patches at discharge or extended quitline telephone counseling post-discharge.","Depending assigned condition, smokers receive nicotine patches discharge extended quitline telephone counseling post-discharge.",C0725813|C1516050|C0012634|C0337664|C1514756|C0028040|C0994894|C0012621|C0231448|G0000000|C0039457|C0010210|C0687676
Children aged 12–59 months were randomly assigned to receive either albendazole or placebo every four months for 12 months with a follow-up at 14 months.,Children aged 12–59 months randomly assigned receive albendazole placebo months 12 months follow-up 14 months.,C0008059|C0001779|G0000000|C0439231|G0000000|C1516050|C1514756|C0001911|C0032042|C0439231|C0450371|C0439231|C0589120|C0450371|C0439231
The patients in group A received rTMS over the brain cortex where motor evoked potential (MEP) was obtained from the suprahyoid muscle.,The patients A received rTMS brain cortex motor evoked potential (MEP) suprahyoid muscle.,G0000000|C0030705|G0000000|C1514756|G0000000|C0006104|C0007776|C1513492|C1444748|C3245505|C1707163|G0000000|C0026845
"Using a 1:1 ratio, women were randomized to either the NRT patch and continued CBT (Group 1) or CBT only (Group 2).","Using 1:1 ratio, women randomized NRT patch continued CBT (Group 1) CBT (Group 2).",C1524063|G0000000|C0456603|C0043210|C0034656|C1278444|C0332461|C0549178|C0009244|C0441833|G0000000|C0009244|C0441833|G0000000
"After subjects were assessed for eligibility, they returned for a baseline visit, at which eligible subjects were randomized into treatment with either nicotine or placebo gum dispensed by a research study nurse at each study visit.","After subjects assessed eligibility, returned baseline visit, eligible subjects randomized treatment nicotine placebo gum dispensed study nurse study visit.",G0000000|C0681850|C1516048|C0013893|C0332156|C0168634|C0545082|C1548635|C0681850|C0034656|C0039798|C0028040|C0032042|C0017562|C1880359|C0557651|C0028661|C0557651|C0545082
Our study was a randomized trial comparing the impact of a 12-month exercise intervention versus usual care (control) on AI-induced arthralgia.,Our study randomized trial comparing impact 12-month exercise intervention versus usual care (control) AI-induced arthralgia.,G0000000|C0557651|C0034656|C0008976|C1707455|C1825598|C0450371|C0015259|C0886296|G0000000|C3538928|C1947933|C0243148|C0003353|C0003862
"In three independent randomisations, 2507 pregnant women were allocated to receive single-dose albendazole or placebo, and praziquantel or placebo; 2016 of their offspring were randomised to receive quarterly single-dose albendazole or placebo from age 15 months to 5 years.","In independent randomisations, 2507 pregnant women allocated receive single-dose albendazole placebo, praziquantel placebo; 2016 offspring randomised receive quarterly single-dose albendazole placebo age 15 months 5 years.",G0000000|C0085862|G0000000|G0000000|C0549206|C0043210|G0000000|C1514756|C0037179|C0001911|C0032042|C0032911|C0032042|G0000000|C0680063|G0000000|C1514756|C0332179|C0037179|C0001911|C0032042|C0001779|C0450371|C0439231|G0000000|C0439234
"After randomization, patients in the Prehab group received a personalized, supervised, and home-based multimodal program prescribed by a kinesiologist (R.A.), a nutritionist, and a psychology-trained nurse.","After randomization, patients Prehab received personalized, supervised, home-based multimodal program prescribed kinesiologist (R.A.), nutritionist, psychology-trained nurse.",G0000000|C0034656|C0030705|G0000000|C1514756|C1709510|G0000000|C0442519|C1513743|C1709697|C0278329|G0000000|C0205090|C0237083|C0004936|C0028661
"Infants who tolerated 100 mL/kg/day enteral feeding were randomly categorized into two groups; Group I, (intervention group or PDF fortified human milk group) PDF+Bebelac Premature formula, and group II (Controls or non intervention group) with no fortification of breast milk+Babelac Premature formula.","Infants tolerated 100 mL/kg/day enteral feeding randomly categorized groups; Group I, (intervention PDF fortified human milk group) PDF+Bebelac Premature formula, II (Controls intervention group) fortification breast milk+Babelac Premature formula.",C0021270|G0000000|C1442061|C1532579|C1304890|C0204695|G0000000|C0871968|C0441833|C0441833|C0021966|C0886296|C1431343|G0000000|C0086418|C0026131|C0441833|C1431343|C0151526|C0489829|G0000000|C0243148|C0886296|C0441833|G0000000|C0006141|C0026131|C0151526|C0489829
"From age 2 to 5 years, children received chewable tablets of albendazole (400 mg) or matching placebo, packaged and sealed by an independent committee of Medical Research Council staff in Entebbe, not otherwise involved in the study, into consecutively numbered envelopes according to the randomisation code.","From age 2 5 years, children received chewable tablets albendazole (400 mg) matching placebo, packaged sealed independent committee Medical Research Council staff Entebbe, involved study, consecutively numbered envelopes randomisation code.",G0000000|C0001779|G0000000|G0000000|C0439234|C0008059|C1514756|G0000000|C0039225|C0001911|C1442061|C0026410|C0150103|C0032042|C0030176|C0036492|C0085862|C2699414|C0199168|C0035168|C1551807|C0851286|G0000000|C1314939|C0557651|G0000000|C0449788|C1622204|C0034656|C0009219
"In both treatment groups, for cases in which the maintenance dosage did not achieve the reduction in ICP to below the 20 mmHg threshold, the maintenance dosage for both drugs could be increased by 1 mg/kg per hour, while looking for electroencephalographic burst suppression or even the flat pattern, in order to ensure that different doses of the two barbiturates were equipotent.","In treatment groups, maintenance dosage achieve reduction ICP 20 mmHg threshold, maintenance dosage drugs increased 1 mg/kg hour, electroencephalographic burst suppression flat pattern, ensure doses barbiturates equipotent.",G0000000|C0039798|C0441833|C0024501|C0178602|G0000000|C0301630|C1881201|C0450371|C0439475|C0449864|C0024501|C0178602|C0013227|C0205217|G0000000|C0439272|C0439227|C0013819|C0439818|C0221103|C0205324|C0449774|C0218063|C0178602|C0004745|G0000000
Patients fulfilling selection criteria were randomized to receive trial drugs supplied by Sponsor as per randomization schedule in 1:1:1 ratio involving three study groups.,Patients fulfilling selection criteria randomized receive trial drugs supplied Sponsor randomization schedule 1:1:1 ratio involving study groups.,C0030705|C1550543|C0036576|C0243161|C0034656|C1514756|C0008976|C0013227|C1999230|C1711305|C0034656|C0086960|G0000000|C0456603|C1314939|C0557651|C0441833
"All patients received darbepoetin alfa once every 3 weeks and were randomly assigned to receive either ferric gluconate 187.5 mg intravenously (IV) every 3 weeks, oral daily ferrous sulfate 325 mg, or oral placebo for 16 weeks.","All patients received darbepoetin alfa 3 weeks randomly assigned receive ferric gluconate 187.5 intravenously (IV) 3 weeks, oral daily ferrous sulfate 325 mg, oral placebo 16 weeks.",G0000000|C0030705|C1514756|G0000000|C0439095|G0000000|C0439230|G0000000|C1516050|C1514756|C2346593|C0017714|C1442061|G0000000|C0022326|G0000000|C0439230|C0442027|C0332173|C2346592|C0038720|C1442061|C0026410|C0442027|C0032042|C0450371|C0439230
"We compared acceptability, adherence and efficacy of trans-dermal nicotine patches and cognitive behavioral therapy (Group 1) to cognitive behavioral therapy alone (Group 2) in minority pregnant smokers.","We compared acceptability, adherence efficacy trans-dermal nicotine patches cognitive behavioral therapy (Group 1) cognitive behavioral therapy (Group 2) minority pregnant smokers.",G0000000|C1707455|C0814633|C1510802|C1280519|C2826298|C0028040|C0994894|C1516691|C0004927|C0039798|C0441833|G0000000|C1516691|C0004927|C0039798|C0441833|G0000000|C0026192|C0549206|C0337664
"If the ICP was not lowered to below 20 mmHg, then the protocol permitted a second bolus of 3 mg/kg, which could be readministered at 5 mg/kg if necessary to reduce persistently elevated ICP.","If ICP lowered 20 mmHg, protocol permitted bolus 3 mg/kg, readministered 5 mg/kg reduce persistently elevated ICP.",G0000000|C1881201|C0441994|C0450371|C0439475|C0442711|C0329040|C1511237|G0000000|C0439272|G0000000|G0000000|C0439272|G0000000|C0750508|C0205250|C1881201
"Two hundred and nine subjects were allocated to Active NRT, and 105 to Placebo.","Two subjects allocated Active NRT, 105 Placebo.",C0205448|C0681850|G0000000|C0205177|C1278444|C1442061|C0032042
"The interventions are (1) nicotine patches (eight-week, step down program) dispensed at discharge and (2) proactive telephone counseling provided by the state quitline after discharge.","The interventions (1) nicotine patches (eight-week, step program) dispensed discharge (2) proactive telephone counseling provided quitline discharge.",G0000000|C0886296|G0000000|C0028040|C0994894|C0205454|C1261552|C1709697|C1880359|C0012621|G0000000|G0000000|C0039457|C0010210|C1999230|G0000000|C0012621
"The treatment period was 2 weeks (5 days per week, 20 minutes per session).","The treatment period 2 weeks (5 days week, 20 minutes session).",G0000000|C0039798|C0439531|G0000000|C0439230|G0000000|C0439228|C0332174|C0450371|C0439232|C1883016
The maintenance dosage was an infusion of thiopental at a rate of 3 mg/kg per hour.,The maintenance dosage infusion thiopental rate 3 mg/kg hour.,G0000000|C0024501|C0178602|C0574032|C0039925|C0871208|G0000000|C0439272|C0439227
"Fortification was started with 22 cal/fl oz for 2 to 4 days then 24 cal/ fl oz, if tolerated 27 cal/fl oz was used till the infant reached 1800 g, which was set as discharge weight in our unit.","Fortification started 22 cal/fl oz 2 4 days 24 cal/ fl oz, tolerated 27 cal/fl oz till infant reached 1800 g, set discharge weight unit.",G0000000|C1272689|C0450371|C0439259|C0439218|G0000000|G0000000|C0439228|C0450371|C0439259|C1708024|C0439218|G0000000|C0450371|C0439259|C0439218|G0000000|C0021270|C2584321|G0000000|C0439267|C0036849|C0012621|C0005910|C0439148
"The intervention consisted of a distribution of a 400-mg albendazole dose (two tablets of 200 mg, per national Chinese treatment guidelines) accompanied by two educational pamphlets (one for children and one for parents) about STH infection, treatment, and prevention (Figure 3 ).","The intervention consisted distribution 400-mg albendazole dose (two tablets 200 mg, national Chinese treatment guidelines) accompanied educational pamphlets (one children parents) STH infection, treatment, prevention (Figure 3 ).",G0000000|C0886296|C0332529|C0520511|C1442061|C0001911|C0178602|C0205448|C0039225|C1442061|C0026410|C3245503|C0008120|C0039798|C0162791|G0000000|C0587721|C0030258|C0205447|C0008059|C0030551|C1846860|C0009450|C0039798|C0199176|G0000000|G0000000|G0000000
"To compare the cost-effectiveness of three intervention conditions: patches alone, counseling alone, and the combined interventions, against the usual care condition.","To compare cost-effectiveness intervention conditions: patches alone, counseling alone, combined interventions, usual care condition.",C0040363|C1707455|C0010181|C0886296|C0012634|C0994894|C0205171|C0010210|C0205171|C0205195|C0886296|C3538928|C1947933|C0012634
"The objective was to assess whether 25% ALB therapy (2g/kg intravenously administered over 120 minutes) compared to an equal volume of 0.9% normal saline conferred neuroprotection in acute ischemic stroke, over and above the standard of care, in two cohorts of patients with acute ischemic stroke.","The objective assess 25% ALB therapy (2g/kg intravenously administered 120 minutes) compared equal volume 0.9% normal saline conferred neuroprotection acute ischemic stroke, standard care, cohorts patients acute ischemic stroke.",G0000000|C0018017|C1516048|C0450371|G0000000|C0039798|C0017209|G0000000|C1521801|C1442061|C0439232|C1707455|C0205163|C0449468|G0000000|C0205307|C0036082|G0000000|C0598958|C0205178|C0475224|C0038454|C1442989|C1947933|C0599755|C0030705|C0205178|C0475224|C0038454
"The initial ‘Treatment Phase’ involved three groups receiving either sertaconazole 2% cream applied topically twice daily for four weeks, terbinafine 1% cream once daily for two weeks, luliconazole 1% cream once daily for two weeks.","The initial ‘Treatment Phase’ involved receiving sertaconazole 2% cream applied topically daily weeks, terbinafine 1% cream daily weeks, luliconazole 1% cream daily weeks.",G0000000|C0205265|G0000000|G0000000|C1314939|C1514756|C0074391|G0000000|C0700385|C4048755|G0000000|C0332173|C0439230|C0076110|G0000000|C0700385|C0332173|C0439230|C1956280|G0000000|C0700385|C0332173|C0439230
"Eligible infants were randomized and stratified within center by gestational strata (230/7–266/7 vs. 270/7–296/7wks), to placebo or one of 3 daily doses of inositol.","Eligible infants randomized stratified center gestational strata (230/7–266/7 vs. 270/7–296/7wks), placebo 3 daily doses inositol.",C1548635|C0021270|C0034656|C0205363|C0205099|C0439671|G0000000|G0000000|G0000000|G0000000|C0032042|G0000000|C0332173|C0178602|C0021547
All eligible children received either treatment or placebo tablets on four occasions.,All eligible children received treatment placebo tablets occasions.,G0000000|C1548635|C0008059|C1514756|C0039798|C0032042|C0039225|C0521114
